Fabbro M, et al. - In the ENGOT-OV16/NOVA trial, researchers studied the safety and efficacy of niraparib in subjects of age ≥70 years with recurrent ovarian cancer. They noticed that non-gBRCAmut subjects of age ≥70 years getting niraparib had a median progression-free survival (PFS) of 11.3 months when compared with 3.8 months in the placebo arm. They found 17.3 months, the median duration of follow-up in the niraparib arm in subjects ≥70 years and 17.2 months in patients <70 years. They observed the most common grade ≥ 3 adverse events (AEs) in patients ≥70 years were hematologic as thrombocytopenia event (34.4%), anemia event (13.1%), and neutropenia event (16.4%). They suggested PFS benefits and incidence of any grade or serious treatment-emergent AEs equivalent to the outcomes in the younger population vs subjects ≥70 years of age receiving niraparib as maintenance therapy in the ENGOT-OV16/NOVA trial.